Publications by authors named "M Schiappacassi"
Article Synopsis
- Head and Neck Squamous Cell Cancer (HNSCC) is a significant health concern, ranking sixth among global cancers, with a pressing need for new therapies and biomarkers due to slow advancements in treatment personalization.!* -
- This study analyzed the somatic mutations in 15 specific genes related to HNSCC in a high-incidence area of Italy, finding unique mutation patterns that may have prognostic implications, particularly in the hypopharyngeal region.!* -
- The research revealed that while certain mutations indicate poorer prognosis, they currently lack sufficient evidence to be used as predictive biomarkers, highlighting the necessity for further studies to improve treatment options for HNSCC patients.!*
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic effect by both trapping PARP1 on the damaged DNA and by restraining its enzymatic activity (PARylation). How PARP1 is recruited and trapped at the DNA damage sites and how resistance to PARPi could be overcome are still matters of investigation.
View Article and Find Full Text PDFPlatinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known about how the acquisition of PT-resistance mediates the increased spreading capabilities of EOC. Here, using isogenic PT-resistant cells, genetic and pharmacological approaches, and patient-derived models, we report that Integrin α6 (ITGA6) is overexpressed by PT-resistant cells and is necessary to sustain EOC metastatic ability and adhesion-dependent PT-resistance.
View Article and Find Full Text PDF